Your Article Summary
See Latest ArticlesRoche announced that two-year data from the LITHE study demonstrated that ACTEMRA continued to inhibit the progression of structural damage to joints in patients with rheumatoid arthritis. The study also showed that patients receiving ACTEMRA experienced improved physical function, as measured by the Health Assessment Questionnaire Disability Index scores. The LITHE study is the fifth international Phase III study in the extensive ACTEMRA clinical development program to successfully meet its primary endpoints in patients with moderately to severely active RA.
Today in Physician/Patient Trends...keeping you current
Receive free subspecialty "5-minute updates" via email
Surgical and minimally invasive treatments for Peyronie's disease
Current Opinion in Urology, 11/19/09
Trends in prescribing and self-poisoning in relation to UK regulatory authority warnings against use of SSRI antidepressants in under-18-year-olds
British Journal of Clinical Pharmacology, 11/02/09
Derivation and Validation of the ASK-12 Adherence Barrier Survey
Annals of Pharmacotherapy, 10/15/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Bayer Team wins the “Deutscher Zukunftspreis” awarded by the German President
BayNews International, 12/03/09
GSK Update: GSKs Arepanrix H1N1 pandemic vaccine prequalified by the World Health Organization
GlaxoSmithKline, 12/02/09
Bayer Schering Pharma to collaborate with Micromet on novel approach to cancer therapy
BayNews International, 12/02/09